MedPath

Efficacy of Phlai capsule and loratadine as treatment in allergic rhinitis patients

Phase 2
Conditions
Peak nasal inspiration flow
Efficacy of Phlai capsule in allergic rhinitis patient
Total nasal symptom scores
Ocular scores
Visual analogue scale
Registration Number
TCTR20171111002
Lead Sponsor
Thai Traditional Medical Knowledge Fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Enrolling by invitation
Sex
All
Target Recruitment
75
Inclusion Criteria

1.age between 18-50 years old
2. Diagnose of allergic rhinitis (at least mild intermittent)
3. Daily Total nasal symptoms score 6-10 on 3 consecutive day
4. Skin test positive at least one from five aeroallergen (house dust mite, cockroach, cat hair, dog dander, Bermuda grass)
5. Do not use
- Intradermal nasal steroid 2 week
- Systemic corticosteroid 2 week
- Antihistamine 1 week
- Intranasal or systemic decongestant 3 day
6. No smoking
7. No alcohol use
8. No allergic history to herb

Exclusion Criteria

1. Have chronic illness or underlying disease (heart is ease, renal disease ,liver disease)
2. During on immunotherapy for allergic rhinitis treatment
3.Asthmatic patient
4.Take antidepressant, sedative ,anxiolytics, opioids, neuroleptic drug
5. After intranasal surgery within 6 months
6. Nasal polyp, nasal septum deviation, acute or chronic rhinosinusitis
7. Pregnancy or lactation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total nasal symptom score 8 wk Sum of score
Secondary Outcome Measures
NameTimeMethod
Quality of life 8 wk Sum of score,Peak nasal inspiration flow 8 wk Mean score,Visual analogue scale score 8 wk Mean
© Copyright 2025. All Rights Reserved by MedPath